Literature DB >> 22358974

IL-2 induces the release of secondary cytokines which stimulate the cytotoxic activity of either NK or CD8(+) lymphocytes.

U Testa1, D Bulgarini, E Montesoro, E Tritarelli, G Boccoli, A Camagna, F Calabresi, C Peschle.   

Abstract

Entities:  

Year:  1991        PMID： 22358974     DOI： 10.1007/BF00736828

Source DB:  PubMed          Journal:  Cytotechnology        ISSN： 0920-9069            Impact factor:   2.058


× No keyword cloud information.
  8 in total

Review 1.  Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.

Authors:  S A Rosenberg
Journal:  Important Adv Oncol       Date:  1986

2.  Adoptive immunotherapy of human cancer: the cytokine cascade and monocyte activation following high-dose interleukin 2 bolus treatment.

Authors:  G Boccoli; R Masciulli; E M Ruggeri; P Carlini; G Giannella; E Montesoro; G Mastroberardino; G Isacchi; U Testa; F Calabresi
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

3.  Adoptive immunotherapy with high-dose interleukin-2: kinetics of circulating progenitors correlate with interleukin-6, granulocyte colony-stimulating factor level.

Authors:  E Tritarelli; E Rocca; U Testa; G Boccoli; A Camagna; F Calabresi; C Peschle
Journal:  Blood       Date:  1991-02-15       Impact factor: 22.113

4.  Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients.

Authors:  J W Mier; G Vachino; J W van der Meer; R P Numerof; S Adams; J G Cannon; H A Bernheim; M B Atkins; D R Parkinson; C A Dinarello
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

5.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

6.  Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients.

Authors:  S E Ettinghausen; J G Moore; D E White; L Platanias; N S Young; S A Rosenberg
Journal:  Blood       Date:  1987-06       Impact factor: 22.113

7.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Authors:  M T Lotze; Y L Matory; S E Ettinghausen; A A Rayner; S O Sharrow; C A Seipp; M C Custer; S A Rosenberg
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

8.  Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes.

Authors:  E A Grimm; A Mazumder; H Z Zhang; S A Rosenberg
Journal:  J Exp Med       Date:  1982-06-01       Impact factor: 14.307
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.